144 related articles for article (PubMed ID: 30446002)
1. How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2018 Nov; 20(1):255. PubMed ID: 30446002
[TBL] [Abstract][Full Text] [Related]
2. The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Arthritis Res Ther; 2017 Dec; 19(1):283. PubMed ID: 29268756
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
4. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Dec; 76(12):2065-2070. PubMed ID: 28830881
[TBL] [Abstract][Full Text] [Related]
6. Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Rheumatology (Oxford); 2018 Dec; 57(12):2183-2189. PubMed ID: 30107437
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
8. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
[TBL] [Abstract][Full Text] [Related]
9. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Dalbeth N; Billington K; Doyle A; Frampton C; Tan P; Aati O; Allan J; Drake J; Horne A; Stamp LK
Arthritis Rheumatol; 2019 Oct; 71(10):1739-1746. PubMed ID: 31081595
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
11. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
12. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
13. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
14. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
15. Predicting allopurinol response in patients with gout.
Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Toprover M; Crittenden DB; Modjinou DV; Oh C; Krasnokutsky S; Fisher MC; Keenan RT; Pillinger MH
Bull Hosp Jt Dis (2013); 2019 Mar; 77(2):87-91. PubMed ID: 31140959
[TBL] [Abstract][Full Text] [Related]
17. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
19. Relation between adverse events associated with allopurinol and renal function in patients with gout.
Vázquez-Mellado J; Morales EM; Pacheco-Tena C; Burgos-Vargas R
Ann Rheum Dis; 2001 Oct; 60(10):981-3. PubMed ID: 11557658
[TBL] [Abstract][Full Text] [Related]
20. The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools).
Wright DFB; Hishe HZ; Stocker SL; Dalbeth N; Horne A; Drake J; Haslett J; Phipps-Green AJ; Merriman TR; Stamp LK
Br J Clin Pharmacol; 2024 May; 90(5):1268-1279. PubMed ID: 38359899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
